Legal & General Group PLC Apellis Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 101,358 shares of APLS stock, worth $2.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,358

Previous 85,844 18.07%

Holding current value

$2.99 Million

Previous $5.05 Million 22.93%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $590,617 - $926,340	15,514 Added 18.07%	101,358 $3.89 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $131,440 - $171,971	2,373 Added 2.84%	85,844 $5.05 Million
Q4 2023 Feb 15, 2024	BUY	$37.14 - $64.82 $62,878 - $109,740	1,693 Added 2.07%	83,471 $5 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $56,121 - $211,719	-2,373 Reduced 2.82%	81,778 $3.11 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $193,003 - $234,861	-2,517 Reduced 2.9%	84,151 $7.67 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $292,305 - $420,107	6,274 Added 7.8%	86,668 $5.72 Million
Q4 2022 Feb 14, 2023	SELL	$43.24 - $61.04 $10,723 - $15,137	-248 Reduced 0.31%	80,394 $4.16 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $59,620 - $92,787	-1,332 Reduced 1.62%	80,642 $5.51 Million
Q2 2022 Aug 22, 2022	BUY	$35.07 - $59.21 $407,408 - $687,842	11,617 Added 16.51%	81,974 $3.71 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $42,197 - $64,402	1,190 Added 1.72%	70,357 $3.58 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $346,378 - $553,934	11,268 Added 19.46%	69,167 $3.27 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $382,828 - $851,489	12,192 Added 26.67%	57,899 $1.91 Million
Q2 2021 Aug 12, 2021	BUY	$40.9 - $64.9 $24,949 - $39,589	610 Added 1.35%	45,707 $2.89 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $2,856 - $4,017	-70 Reduced 0.15%	45,097 $1.94 Million
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $155,089 - $288,116	5,037 Added 12.55%	45,167 $2.58 Million
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $501,929 - $652,372	19,387 Added 93.46%	40,130 $1.21 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $226,572 - $351,644	9,136 Added 78.71%	20,743 $678,000
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $13,719 - $33,956	-766 Reduced 6.19%	11,607 $329,000
Q4 2019 Feb 13, 2020	BUY	$22.1 - $30.8 $41,923 - $58,427	1,897 Added 18.11%	12,373 $379,000
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $40,446 - $56,938	2,247 Added 27.31%	10,476 $265,000
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $22,468 - $34,764	1,754 Added 27.09%	8,229 $161,000
Q4 2018 Feb 15, 2019	BUY	$11.47 - $18.71 $5,012 - $8,176	437 Added 7.24%	6,475 $86,000
Q3 2018 Nov 20, 2018	BUY	$16.57 - $21.03 $10,820 - $13,732	653 Added 12.13%	6,038 $108,000
Q2 2018 Aug 10, 2018	BUY	$19.63 - $30.0 $68,763 - $105,090	3,503 Added 186.13%	5,385 $118,000
Q4 2017 Feb 13, 2018	BUY	$12.71 - $21.7 $23,920 - $40,839	1,882	1,882 $41,000

Others Institutions Holding APLS

# of Institutions

299

Shares Held

113M

Call Options Held

5.21M

Put Options Held

691K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.24B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Apellis Pharmaceuticals, Inc. Transaction History